Lupin Ltd Share Price (LUPIN)

Sharekhan Recommends Buying Lupin with Target Price of Rs. 1868 - 16 Apr, 2024

Lupin's US sales are expected to reach $1 billion by FY2026, and EBITDA margin is expected to rise to a five-year high at 21%. Sharekhan recommends buying Lupin with a target price of Rs. 1868 due to healthy uptick in respiratory portfolio led by gSpiriva witnessing a 30-35% conversion rate.

Lupin Forecasts $200-210 Million Quarterly Sales for US Operations - 15 Apr, 2024

Lupin expects to generate $200-210 million in quarterly sales from its US operations this year, with the respiratory portfolio driving future revenue growth. The company also plans to diversify into other therapeutic areas such as injectables.

Lupin Reports Strong Q3 Results and Successful FDA Inspection - 12 Apr, 2024

Lupin Ltd shares rose over 2% after the company announced successful closure of inspections by the USFDA at its Vadodara facility. The pharmaceutical company reported a consolidated net profit of Rs 613.12 crore in Q3 FY24, growing 299.6% YoY, while revenue from operations increased 20.2% YoY to Rs 5,197.4 crore. Lupin's API manufacturing facility located at Dabhasa, Gujarat has completed the USFDA inspection with no observations.

Lupin Launches First Generic Version of Oracea in US Market; Receives Approval from USFDA - 10 Apr, 2024

Lupin has launched its first generic version of Oracea in the US market after receiving approval from the USFDA. Brokerage Nomura has maintained a buy rating on Lupin with an increased target price of Rs 1,949 per share. The company also recalled Rifampin Capsules due to subpotency.

Lupin Launches Generic Version of Oracea and Secures Approval for Tardive Dyskinesia Treatment Drug - 09 Apr, 2024

Lupin has launched a generic version of Oracea skin treatment capsules in the US and secured FDA approval for selling Valbenazine Capsules, used to treat involuntary movements resulting from tardive dyskinesia. However, Lupin is recalling 26,352 bottles of Rifampin capsules in the US market due to a sub-potent drug identified from its Aurangabad plant.

Lupin Receives FDA Approval for Generic Equivalent - 08 Apr, 2024

Lupin Limited has received FDA approval to market Valbenazine Capsules, a generic equivalent of Neurocrine Biosciences' Ingrezza Capsules, used to treat involuntary movements caused by tardive dyskinesia.

Lupin Appoints Dr. Ranjana Pathak as Chief Quality Officer - 04 Apr, 2024

Dr. Ranjana Pathak has been appointed as the new Chief Quality Officer of Lupin Limited, succeeding Johnny Mikell who is retiring. With over three decades of industry experience, Pathak will oversee all aspects of quality and regulatory compliance for Lupin's global operations.

Lupin's Q3 Net Profit Soars to Rs 916 Crore - 03 Apr, 2024

Lupin Ltd reported a net profit of Rs 916 crore in the December quarter, up from Rs 40.4 crore a year ago. Its operating profit margins expanded to 29.58 percent and revenue jumped to Rs 4,138 crore. SBI Securities is bullish on the stock given its strong quarterly results, leadership in certain geographies, and strong product portfolio and pipeline.

Lupin Receives Multiple FDA Approvals - 01 Apr, 2024

Lupin has received multiple approvals from the USFDA for its drugs, including Eslicarbazepine Acetate tablets and Migalastat Capsules, potentially granting the company 180-day exclusivity with estimated sales of $354 million.

Lupin Receives US FDA Approval for Generic Drug; Expects Strong Revival in US Market - 29 Mar, 2024

Lupin has received US FDA approval for its ANDA for Eslicarbazepine Acetate Tablets and may be eligible for 180 days of shared generic exclusivity. Lupin also expects a strong revival in the US market with the launch of gSpiriva, which could generate $150-200 million in sales in the first year alone.

Lupin Stock Surges; Receives FDA Approval for Generic Drug - 28 Mar, 2024

Lupin Ltd's stock has surged 146% over the past year and gained 22% YTD. The company received USFDA approval to market Eslicarbazepine Acetate tablets, with estimated annual sales of $354 million in the US.

Lupin Receives Demand Order from Income Tax Department - 27 Mar, 2024

Lupin has received a demand order of Rs 477.28 crore from the Income Tax Department for assessment year 2021-22. The company plans to file a rectification application and appeal before the appellate authority. Bernstein has maintained its outperform and underperform ratings on major pharma companies, including Lupin.

Lupin to Sell Trade Generics Business in India - 26 Mar, 2024

Pharmaceutical company Lupin is set to sell its trade generics businesses in India for Rs 100-120 crore on a slump sale basis. The move will see the transfer of all related assets and liabilities, including movable assets, products, employees, contracts, intellectual property, licenses, permits, consents, approvals, transferable tax credits, trade receivables, inventory, trade payables, and insurance policies to wholly-owned subsidiary Lupin Life Sciences Limited.

Lupin to Transfer Trade Generics Business to Wholly-Owned Subsidiary - 25 Mar, 2024

Lupin Ltd plans to transfer its trade generics business in India to Lupin Life Sciences Ltd, a wholly-owned subsidiary of the company, for Rs 100-120 crore. The agreement is expected to be finalized in Q1 of FY25.

Lupin Ltd's Stock Increases by 27% in Three Months - 24 Mar, 2024

Lupin Ltd's stock has increased significantly by 27% over the past three months. The company's respectable earnings growth can be explained by its low payout ratio of 24%, which suggests that most profits are being invested to grow the business. This is expected to increase the company's ROE to 17%.

Lupin to Transfer Trade Generics Business to Wholly-Owned Subsidiary - 22 Mar, 2024

Lupin is planning to transfer its trade generics business in India to Lupin Life Sciences Ltd, a wholly-owned subsidiary of the company, for ₹100-120 crore. The slump sale is expected to be completed by June 30, 2024, subject to securing requisite approvals.

Lupin Receives FDA Approval and Appoints New CTO - 19 Mar, 2024

Lupin announces two significant events - receiving FDA approval for its Abbreviated New Drug Application for Doxycycline for Injection USP and appointing Christoph Funke as Chief Technical Operations Officer.

Lupin Appoints New CTO; Shares Slip After FDA Observation - 18 Mar, 2024

Lupin Ltd appoints Christoph Funke as Chief Technical Operations Officer while the company's shares slip by 1.5% following an FDA observation at its Aurangabad facility.